| Literature DB >> 28043182 |
Marie Iwanaga1,2, Yukinobu Kodama1, Takahiro Muro1, Hiroo Nakagawa1, Tomoaki Kurosaki1, Kayoko Sato1, Tadahiro Nakamura1, Takashi Kitahara1, Hitoshi Sasaki1,2.
Abstract
The purpose of this study was to develop a ternary complex of plasmid DNA (pDNA) electrostatically assembled with dendrigraft poly-l-lysine (DGL) and biodegradable glycosaminoglycan for effective and secure gene delivery. High gene expression of pDNA/DGL complex was confirmed with slight cytotoxicity and erythrocyte agglutination. Anionic ternary complexes of 55.4-223.8 nm were formed by the addition of a glycosaminoglycan such as chondroitin sulfate A (CS-A), chondroitin sulfate B (CS-B), chondroitin sulfate C (CS-C) or hyaluronic acid (HA). Using the cell line B16-F10, most of the ternary complexes showed only weak gene expression and little cytotoxicity, although the pDNA/DGL/CS-A complexes maintained a certain level of gene expression. In particular, the pDNA/DGL/CS-A8 complexes showed significantly higher gene expression than pDNA/DGL complexes in the presence of fetal bovine serum. Gene expression from the pDNA/DGL/CS-A8 complex was inhibited by a high concentration of CS-A and endocytosis inhibitors. After intravenous administration of the pDNA/DGL/CS-A8 complex and the pDNA/DGL complex into ddY mice, high gene expression was observed in the reticuloendothelial systems, the pDNA/DGL/CS-A complex is expected to be useful for gene therapy.Entities:
Keywords: Dendrigraft poly-l-lysine; biodegradable; chondroitin sulfate; drug delivery; gene therapy; glycosaminoglycan; hyaluronic acid
Mesh:
Substances:
Year: 2017 PMID: 28043182 DOI: 10.1080/1061186X.2016.1274996
Source DB: PubMed Journal: J Drug Target ISSN: 1026-7158 Impact factor: 5.121